In Brief: Adjunctive Pramipexole for Treatment-Resistant Depression

The oral nonergot dopamine agonist pramipexole (Mirapex ER, and generics), which is FDA-approved for treatment of Parkinson's disease and restless legs syndrome, has been used off-label in patients with treatment-resistant depression (TRD).1 A double-blind, placebo-controlled trial of pramipexole augmentation in patients with unipolar TRD was recently published.